Clinical study about the hypotensive effect and the inhibitory effect on the elevation of uric acid level by irbesartan and trichlormethiazide in the essential hypertensive patients.

Clinical study about the hypotensive effect and the inhibitory effect on the elevatin of uric acid level irbesartan and trichlormethiazide in the essential hypertension patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1090220183

Enrollment

100

Registered

2014-06-25

Start date

2013-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Intervention type: Name of intervention: Dose form / Japanese Medical Device Nomenclature: Route of administration / Site of application: Dose per administration: Dosing frequency / Frequency of use:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Essential hypertensive patients who have been taking ARB except irbesartan (IrbetanR) and losartan and concomitantly with trichlormethiazide (FluitranR) 1 mg, and have not changed these medications at least for 8 weeks, whose systolic blood pressure (BP) or diastolic BP at baseline is >=130 or >=80 mmHg respectively and also who signed on informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: Patients with severe hypertension (diastolic BP >=120 mmHg), secondary or malignant hypertension. Patients with recent history of myocardial infarction or stroke within 6 months. Patients with severe hepatic dysfunction (AST >=100 IU/L or ALT >=100 IU/L or bilirubin >=2.5 mg/dL),or with renal dysfunction (serum creatinine >=2.0 mg/dL or e-GFR<30 mL/min/1.73 m2), or type 1 diabetes mellitus, or poorly controlled type 2 diabetes mellitus. Patients with drug or alcohol abuse. Patients who are pregnant or breastfeeding. Patients under participation in other clinical trials. Patients with history of hypersensitivity to irbesartan (IrbetanR) and trichlormethiazide (FluitranR) Patients who took some concomitant drugs prohibited during the previous 8 weeks before the start of study. Patients who are deemed ineligible by investigator.

Design outcomes

Primary

Measure	Time frame
Primary outcome: percent changes of blood pressure from 0 week(baseline) to 12 weeks	—

Secondary

Measure	Time frame
Secondary outcome: Changes of serum uric acid from 0 week(baseline) to 12 weeks	—

Countries

Japan

Contacts

Public ContactHiroyuki Mizuta

Nagoya Medical Association

hiroyuki_mizuta@ishikai.nagoya+81-52-979-7071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026